Vertex Pharmaceuticals Inc
Close on Nov 2, 2026Market cap $140.20BP/E 32.2Yield –
Vertex Pharmaceuticals Vertex Europe (UK) by Year
Vertex Europe (UK) — Shared cost-sharing R&D expense with Vertex Inc. ($M) ($M)
Vertex Pharmaceuticals Vertex Europe (UK): $185M in FY2025, up 12.1% from a year earlier.
Where the FY2025 figure comes from
“Amounts payable to Vertex Pharmaceuticals Inc. for the Company's share of development costs on non-North American intellectual property and other development projects with third party collaborators was $185 million (2024: $165 million).”
Source: Vertex Pharmaceuticals (Europe) Limited (02907620) ↗
Reported in UK Companies House Statutory Accounts (02907620, OCR).
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Vertex Europe (UK) — Shared cost-sharing R&D expense with Vertex Inc. ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 185 | +12.1% | Vertex Pharmaceuticals (Europe) Limited (02907620) ↗ |
| FY2024 | Dec 31, 2024 | 165 | +3.8% | Vertex Pharmaceuticals (Europe) Limited (02907620) ↗ |
| FY2023 | Dec 31, 2023 | 159 | -36.7% | Vertex Pharmaceuticals (Europe) Limited (02907620) ↗ |
| FY2022 | Dec 31, 2022 | 251 | +7.3% | Vertex Pharmaceuticals (Europe) Limited (02907620) ↗ |
| FY2021 | Dec 31, 2021 | 234 | +43.6% | Vertex Pharmaceuticals (Europe) Limited (02907620) ↗ |
| FY2020 | Dec 31, 2020 | 163 | +76.8% | Vertex Pharmaceuticals (Europe) Limited (02907620) ↗ |
| FY2019 | Dec 31, 2019 | 92.2 | -27.5% | Vertex Pharmaceuticals (Europe) Limited (02907620) ↗ |
| FY2018 | Dec 31, 2018 | 127 | – | Vertex Pharmaceuticals (Europe) Limited (02907620) ↗ |
Cite this data
StockData. (2026). Vertex Pharmaceuticals Vertex Europe (UK) ($M), annual FY2018–FY2025 [Data set]. Compiled from Vertex Pharmaceuticals SEC filings and investor materials. https://stockdatahq.com/stocks/vrtx/kpis/uk-eur-rd-shared-inc
See every metric in the Vertex Pharmaceuticals KPI table. Data updated Nov 2, 2026.